drugset / Trial / NCT04094298

Use of Extended Release Triamcinolone in the Treatment of Rotator Cuff Disease

NCT04094298

Phase 3 Active not recruiting 65 enrolled Northwell Health
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to assess the overall safety and general tolerability of extended release triamcinolone acetate (TA-ER/FX006) in patient with rotator cuff disease. The study will enroll 65 patients, aged 40-75 years old, in a longitudinal case series level IV study using extended release triamcinolone to treat shoulder pain from rotator cuff disease. Inclusion criteria will be shoulder pain without a history of trauma and physical exam consistent with rotator cuff tendinitis, impingement syndrome or rotator cuff tear.

Timeline

Start
2019-07-15
Primary completion
2024-10-10
Completion
2025-01-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Triamcinolone Other / unclassified 32 mg Other